NASDAQ:HSDT

Helius Medical Technologies Competitors

$16.90
-0.22 (-1.29 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.55
Now: $16.90
$17.06
50-Day Range
$12.41
MA: $15.40
$18.45
52-Week Range
$9.45
Now: $16.90
$34.00
Volume24,518 shs
Average Volume134,469 shs
Market Capitalization$39.06 million
P/E RatioN/A
Dividend YieldN/A
Beta0.72

Competitors

Helius Medical Technologies (NASDAQ:HSDT) Vs. MDT, VAR, MASI, LIVN, CNMD, and INMD

Should you be buying HSDT stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Helius Medical Technologies, including Medtronic (MDT), Varian Medical Systems (VAR), Masimo (MASI), LivaNova (LIVN), CONMED (CNMD), and InMode (INMD).

Medtronic (NYSE:MDT) and Helius Medical Technologies (NASDAQ:HSDT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Medtronic and Helius Medical Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.87$4.79 billion$4.5927.43
Helius Medical Technologies$1.50 million26.04$-9,780,000.00($12.94)-1.31

Medtronic has higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.2% of Medtronic shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 17.4% of Helius Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Medtronic and Helius Medical Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic031912.91
Helius Medical Technologies01202.67

Medtronic presently has a consensus price target of $125.3333, suggesting a potential downside of 0.46%. Helius Medical Technologies has a consensus price target of $20.00, suggesting a potential upside of 18.34%. Given Helius Medical Technologies' higher probable upside, analysts plainly believe Helius Medical Technologies is more favorable than Medtronic.

Profitability

This table compares Medtronic and Helius Medical Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic12.69%9.71%5.30%
Helius Medical Technologies-2,716.85%-328.07%-201.87%

Risk & Volatility

Medtronic has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Summary

Medtronic beats Helius Medical Technologies on 11 of the 15 factors compared between the two stocks.

Helius Medical Technologies (NASDAQ:HSDT) and Varian Medical Systems (NYSE:VAR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Profitability

This table compares Helius Medical Technologies and Varian Medical Systems' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Helius Medical Technologies-2,716.85%-328.07%-201.87%
Varian Medical Systems8.50%18.45%8.08%

Institutional and Insider Ownership

87.0% of Varian Medical Systems shares are owned by institutional investors. 17.4% of Helius Medical Technologies shares are owned by insiders. Comparatively, 0.8% of Varian Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Helius Medical Technologies and Varian Medical Systems, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Helius Medical Technologies01202.67
Varian Medical Systems35001.63

Helius Medical Technologies currently has a consensus target price of $20.00, suggesting a potential upside of 18.34%. Varian Medical Systems has a consensus target price of $159.3571, suggesting a potential downside of 10.00%. Given Helius Medical Technologies' stronger consensus rating and higher probable upside, research analysts clearly believe Helius Medical Technologies is more favorable than Varian Medical Systems.

Earnings and Valuation

This table compares Helius Medical Technologies and Varian Medical Systems' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helius Medical Technologies$1.50 million26.04$-9,780,000.00($12.94)-1.31
Varian Medical Systems$3.17 billion5.13$269.20 million$3.9145.29

Varian Medical Systems has higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than Varian Medical Systems, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Helius Medical Technologies has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Varian Medical Systems has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.

Summary

Varian Medical Systems beats Helius Medical Technologies on 9 of the 14 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Helius Medical Technologies (NASDAQ:HSDT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Earnings and Valuation

This table compares Masimo and Helius Medical Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Masimo$937.84 million14.48$196.22 million$3.2276.32
Helius Medical Technologies$1.50 million26.04$-9,780,000.00($12.94)-1.31

Masimo has higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Masimo and Helius Medical Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Masimo20.30%15.75%13.12%
Helius Medical Technologies-2,716.85%-328.07%-201.87%

Institutional and Insider Ownership

81.6% of Masimo shares are owned by institutional investors. 11.5% of Masimo shares are owned by company insiders. Comparatively, 17.4% of Helius Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Masimo and Helius Medical Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Masimo02502.71
Helius Medical Technologies01202.67

Masimo presently has a consensus target price of $272.20, suggesting a potential upside of 10.77%. Helius Medical Technologies has a consensus target price of $20.00, suggesting a potential upside of 18.34%. Given Helius Medical Technologies' higher possible upside, analysts clearly believe Helius Medical Technologies is more favorable than Masimo.

Risk and Volatility

Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Summary

Masimo beats Helius Medical Technologies on 11 of the 14 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and Helius Medical Technologies (NASDAQ:HSDT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Volatility and Risk

LivaNova has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Profitability

This table compares LivaNova and Helius Medical Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LivaNova-21.88%5.55%3.07%
Helius Medical Technologies-2,716.85%-328.07%-201.87%

Earnings & Valuation

This table compares LivaNova and Helius Medical Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.08 billion3.65$-155,180,000.00$3.0826.41
Helius Medical Technologies$1.50 million26.04$-9,780,000.00($12.94)-1.31

Helius Medical Technologies has lower revenue, but higher earnings than LivaNova. Helius Medical Technologies is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for LivaNova and Helius Medical Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LivaNova04202.33
Helius Medical Technologies01202.67

LivaNova presently has a consensus target price of $69.3333, suggesting a potential downside of 14.76%. Helius Medical Technologies has a consensus target price of $20.00, suggesting a potential upside of 18.34%. Given Helius Medical Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Helius Medical Technologies is more favorable than LivaNova.

Institutional & Insider Ownership

89.1% of LivaNova shares are owned by institutional investors. 0.5% of LivaNova shares are owned by insiders. Comparatively, 17.4% of Helius Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

LivaNova beats Helius Medical Technologies on 7 of the 13 factors compared between the two stocks.

Helius Medical Technologies (NASDAQ:HSDT) and CONMED (NYSE:CNMD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Helius Medical Technologies and CONMED, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Helius Medical Technologies01202.67
CONMED02302.60

Helius Medical Technologies presently has a consensus price target of $20.00, suggesting a potential upside of 18.34%. CONMED has a consensus price target of $103.25, suggesting a potential downside of 20.71%. Given Helius Medical Technologies' stronger consensus rating and higher probable upside, analysts plainly believe Helius Medical Technologies is more favorable than CONMED.

Profitability

This table compares Helius Medical Technologies and CONMED's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Helius Medical Technologies-2,716.85%-328.07%-201.87%
CONMED0.04%9.48%3.75%

Valuation and Earnings

This table compares Helius Medical Technologies and CONMED's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helius Medical Technologies$1.50 million26.04$-9,780,000.00($12.94)-1.31
CONMED$955.10 million3.96$28.62 million$2.6449.32

CONMED has higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Helius Medical Technologies has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.

Summary

CONMED beats Helius Medical Technologies on 8 of the 12 factors compared between the two stocks.

InMode (NASDAQ:INMD) and Helius Medical Technologies (NASDAQ:HSDT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for InMode and Helius Medical Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
InMode00403.00
Helius Medical Technologies01202.67

InMode currently has a consensus price target of $71.50, suggesting a potential downside of 18.11%. Helius Medical Technologies has a consensus price target of $20.00, suggesting a potential upside of 18.34%. Given Helius Medical Technologies' higher probable upside, analysts clearly believe Helius Medical Technologies is more favorable than InMode.

Profitability

This table compares InMode and Helius Medical Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InMode32.57%28.56%24.14%
Helius Medical Technologies-2,716.85%-328.07%-201.87%

Institutional and Insider Ownership

35.7% of InMode shares are held by institutional investors. 17.4% of Helius Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares InMode and Helius Medical Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMode$156.36 million17.85$61.15 million$1.6054.57
Helius Medical Technologies$1.50 million26.04$-9,780,000.00($12.94)-1.31

InMode has higher revenue and earnings than Helius Medical Technologies. Helius Medical Technologies is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

InMode has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Summary

InMode beats Helius Medical Technologies on 11 of the 14 factors compared between the two stocks.


Helius Medical Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Medtronic logo
MDT
Medtronic
2.7$125.91-0.0%$169.74 billion$28.91 billion48.06Analyst Report
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.07-0.0%$16.26 billion$3.17 billion60.43News Coverage
Masimo logo
MASI
Masimo
1.6$245.74-0.7%$13.58 billion$937.84 million63.83
LivaNova logo
LIVN
LivaNova
1.5$81.34-1.8%$3.96 billion$1.08 billion-18.92Analyst Report
Analyst Revision
CONMED logo
CNMD
CONMED
1.6$130.21-0.8%$3.79 billion$955.10 million-3,255.25
InMode logo
INMD
InMode
1.5$87.31-0.1%$2.79 billion$156.36 million62.81Analyst Downgrade
Outset Medical logo
OM
Outset Medical
1.0$53.90-0.2%$2.31 billionN/A0.00Analyst Downgrade
Insider Selling
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$34.17-1.4%$1.14 billion$27.37 million-46.81Insider Selling
Increase in Short Interest
NTUS
Natus Medical
1.1$28.22-0.9%$955.92 million$495.52 million-51.31
AxoGen logo
AXGN
AxoGen
1.7$18.85-3.4%$768.55 million$106.71 million-29.92
TransMedics Group logo
TMDX
TransMedics Group
1.6$27.03-2.1%$739.81 million$23.60 million-19.31Increase in Short Interest
ViewRay logo
VRAY
ViewRay
1.3$4.38-1.4%$704.31 million$87.78 million-4.92
Cutera logo
CUTR
Cutera
1.3$30.17-1.8%$536.51 million$181.71 million-16.67News Coverage
Zynex logo
ZYXI
Zynex
1.8$15.36-0.2%$535.37 million$45.47 million46.55
Edap Tms logo
EDAP
Edap Tms
1.3$9.08-0.3%$264.61 million$50.23 million-151.33Increase in Short Interest
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$7.36-11.4%$171.12 million$3.38 million-3.85Decrease in Short Interest
Gap Up
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$3.88-4.4%$123.35 millionN/A0.00
FONR
FONAR
1.1$18.32-2.9%$120.07 million$85.69 million17.28News Coverage
IRIDEX logo
IRIX
IRIDEX
0.9$7.71-3.0%$119.67 million$43.45 million-14.02
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.15-2.6%$91.68 millionN/A-1.51Increase in Short Interest
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.18-1.8%$90.69 million$10,000.00-1.18Analyst Upgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.79-1.7%$86.77 million$2.39 million-2.27Decrease in Short Interest
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.37-0.4%$32.42 million$5.51 million-0.11Analyst Downgrade
Increase in Short Interest
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.63-5.7%$27.20 million$6.57 million-0.01
STRR
Star Equity
0.1$2.80-5.4%$13.78 million$114.18 million-0.89
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.